HUE063275T2 - Gyógyszerészeti kombináció rákbetegség kezelésére - Google Patents

Gyógyszerészeti kombináció rákbetegség kezelésére

Info

Publication number
HUE063275T2
HUE063275T2 HUE18722621A HUE18722621A HUE063275T2 HU E063275 T2 HUE063275 T2 HU E063275T2 HU E18722621 A HUE18722621 A HU E18722621A HU E18722621 A HUE18722621 A HU E18722621A HU E063275 T2 HUE063275 T2 HU E063275T2
Authority
HU
Hungary
Prior art keywords
cancer
treatment
pharmaceutical combination
pharmaceutical
combination
Prior art date
Application number
HUE18722621A
Other languages
English (en)
Hungarian (hu)
Inventor
Garcia Carles Domenech
Alfon Coriat Jose Alberto
Montoyo Hector Perez
Segura Ginard Miguel Francisco
Lizcano De Vega Jose Miguel
Original Assignee
Ability Pharmaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ability Pharmaceuticals S A filed Critical Ability Pharmaceuticals S A
Publication of HUE063275T2 publication Critical patent/HUE063275T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE18722621A 2017-05-16 2018-05-15 Gyógyszerészeti kombináció rákbetegség kezelésére HUE063275T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17382282 2017-05-16

Publications (1)

Publication Number Publication Date
HUE063275T2 true HUE063275T2 (hu) 2024-01-28

Family

ID=58765794

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18722621A HUE063275T2 (hu) 2017-05-16 2018-05-15 Gyógyszerészeti kombináció rákbetegség kezelésére

Country Status (16)

Country Link
US (2) US11260042B2 (ja)
EP (2) EP3624786B1 (ja)
JP (1) JP7208650B2 (ja)
KR (1) KR102569052B1 (ja)
CN (1) CN110636842A (ja)
AU (1) AU2018269462B2 (ja)
BR (1) BR112019023944A2 (ja)
CA (1) CA3063625A1 (ja)
CL (1) CL2019003288A1 (ja)
ES (1) ES2955524T3 (ja)
HU (1) HUE063275T2 (ja)
IL (1) IL270676B1 (ja)
MX (1) MX2019013683A (ja)
PL (1) PL3624786T3 (ja)
WO (1) WO2018210830A1 (ja)
ZA (1) ZA201907286B (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2955524T3 (es) 2017-05-16 2023-12-04 Ability Pharmaceuticals S A Una combinación farmacéutica para el tratamiento de un cáncer
AU2021220258A1 (en) 2020-02-10 2022-06-30 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258816A (ja) * 1987-04-16 1988-10-26 Nippon Oil & Fats Co Ltd 抗癌剤組成物
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
GB9618420D0 (en) * 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
WO2001017524A1 (en) * 1999-09-09 2001-03-15 Efa Sciences Llc. Methods for treating cell proliferative disorders including cancer
GB0011903D0 (en) 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
RU2284818C2 (ru) 2001-05-10 2006-10-10 Анормед, Инк. Комбинированная химиотерапия
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
MX366137B (es) 2009-05-08 2019-06-28 Pronova Biopharma Norge As Acidos grasos poliinsaturados para el tratamiento de trastornos relacionados a las areas de los trastornos cardiovasculares, metabolicos e inflamatorios.
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
PT2775852T (pt) 2011-10-18 2016-11-08 Nestec Sa Composição para utilização no crescimento cerebral e/ou desenvolvimento cognitivo e/ou psicomotor
NZ626699A (en) 2012-01-06 2017-03-31 Omthera Pharmaceuticals Inc Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
ES2955524T3 (es) 2017-05-16 2023-12-04 Ability Pharmaceuticals S A Una combinación farmacéutica para el tratamiento de un cáncer

Also Published As

Publication number Publication date
EP4234035A3 (en) 2023-11-15
US11260042B2 (en) 2022-03-01
JP7208650B2 (ja) 2023-01-19
AU2018269462A1 (en) 2019-11-28
ZA201907286B (en) 2021-01-27
EP4234035A2 (en) 2023-08-30
JP2020520385A (ja) 2020-07-09
RU2019135507A3 (ja) 2021-09-03
AU2018269462B2 (en) 2024-04-18
PL3624786T3 (pl) 2023-10-30
EP3624786C0 (en) 2023-07-05
MX2019013683A (es) 2020-01-15
CN110636842A (zh) 2019-12-31
IL270676A (ja) 2020-01-30
KR102569052B1 (ko) 2023-08-22
US20210154166A1 (en) 2021-05-27
CL2019003288A1 (es) 2020-05-08
KR20200005573A (ko) 2020-01-15
WO2018210830A1 (en) 2018-11-22
US12053449B2 (en) 2024-08-06
ES2955524T3 (es) 2023-12-04
EP3624786A1 (en) 2020-03-25
IL270676B1 (en) 2024-07-01
BR112019023944A2 (pt) 2020-06-09
EP3624786B1 (en) 2023-07-05
CA3063625A1 (en) 2018-11-22
US20220257554A1 (en) 2022-08-18
RU2019135507A (ru) 2021-06-16

Similar Documents

Publication Publication Date Title
PT3616720T (pt) Composição medicinal para tratamento de cancro
IL290149A (en) Combined treatment for cancer
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
HK1247129A1 (zh) 治療癌症的聯合療法
ZA201806819B (en) Pharmaceutical combinations for the treatment of cancer
HK1251475A1 (zh) 用於癌症治療的聯合療法
IL267795A (en) Combined treatment for cancer
SG11202104923YA (en) Pharmaceutical combination for treatment of cancer
EP3148532A4 (en) Pharmaceutical combination for the treatment of cancer
IL274837B1 (en) Combined treatment for cancer
IL268416A (en) Pharmaceutical combinations for cancer treatment
IL261278A (en) Pharmaceutical compositions for the treatment of cancer
IL275525A (en) A pharmaceutical preparation for the treatment of cancer
IL266993A (en) Combined therapy for cancer treatment
ZA201907286B (en) A pharmaceutical combination for the treatment of a cancer
IL273835A (en) Combined product for cancer treatment
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
IL253642A0 (en) Combined treatment for cancer
IL281782A (en) Drug combination for cancer treatment
GB201713936D0 (en) Pharmaceutical combinations for the treatment of cancer
GB201719584D0 (en) Pharmaceutical compositions for the treatment of cancer
EP3683311A4 (en) MEDICINE FOR THE TREATMENT OF CANCER
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro